<DOC>
	<DOCNO>NCT00158834</DOCNO>
	<brief_summary>This study design evaluate , child asthma , stepwise treatment ( five level vary daily fluticasone propionate 100mcg twice daily fix combination salmeterol fluticasone propionate 50/500 mcg ) base symptom score alone result sub-optimal treatment compare treatment base cumulative symptom score bronchial hyperresponsiveness ( PD20 methacholine ) .</brief_summary>
	<brief_title>Pediatric Asthma Study Using Stepwise Treatment With Two Food And Drug Administration Approved Asthma Medications</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Inclusion criterion : Children document history asthma . Using inhaled steroid 100 mcg 500 mcg twice daily least 1 month study start . Must able perform reproducible lung function test . Must positive RAST skin prick test . During treatment period , patient hyperreactive ( define PD20 methacholine &lt; 150 mcg ) and/or cumulative symptom score 14 base daily record card fill last 2 week runin period . Exclusion criterion : History acute upper low respiratory tract infection , middle ear , sinus infection 4 week prior visit 1 . Admitted hospital due respiratory disease 4 week prior visit 1 . Received oral corticosteroid within 4 week prior visit 1 . Existence disorder affect growth . Clinical laboratory evidence serious systemic disease , suspect hypersensitivity corticosteroid , lactose short/long acting B2agonists .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Children</keyword>
	<keyword>Asthma</keyword>
	<keyword>bronchial hyperresponsiveness</keyword>
	<keyword>symptom</keyword>
</DOC>